GlassScriptPhysician profile
Michael John Rekas
NPI 1174525570
$8,271.12
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,697 · 2020: $1,674 · 2021: $2,099 · 2022: $1,255 · 2023: $1,013 · 2024: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,243.26 | 2019-2024 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $790.06 | 2019-2024 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $628.05 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Grifols USA, LLC | $525.41 | 2019-2024 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $489.84 | 2019-2024 | Xarelto |
| Nestle Healthcare Nutrition INC. | $447.86 | 2021-2023 | |
| Lilly USA, LLC | $407.69 | 2019-2022 | |
| Abbvie INC. | $399.46 | 2021-2023 | |
| Amgen INC. | $395.60 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $377.38 | 2019-2024 | |
| Amarin Pharma, INC. | $319.63 | 2020-2022 | |
| Allergan, INC. | $280.10 | 2019-2020 | |
| Glaxosmithkline, LLC. | $255.79 | 2019-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $222.32 | 2023-2024 | Cologuard Collection Kit |
| Lundbeck LLC | $218.05 | 2022-2024 | Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $201.39 | 2021-2024 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $154.39 | 2019-2024 | Adynovate |
| Teva Pharmaceuticals USA, INC. | $125.47 | 2019-2021 | |
| Eisai INC. | $96.26 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $95.63 | 2021 | |
| Paratek Pharmaceuticals, INC. | $90.32 | 2021 | |
| Ironwood Pharmaceuticals, INC | $88.36 | 2019-2020 | |
| Melinta Therapeutics, LLC | $79.24 | 2019 | |
| Esperion Therapeutics, INC. | $71.22 | 2020-2024 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $58.76 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.52 | 2020 | |
| Phathom Pharmaceuticals, INC. | $45.80 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $29.10 | 2019 | |
| Inspire Medical Systems, INC. | $25.11 | 2023 | Inspire |
| Bausch Health US, LLC | $20.74 | 2022 | |
| Hikma Pharmaceuticals USA | $17.15 | 2023 | Ryaltris |
| Otsuka America Pharmaceutical, INC. | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rekas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.